# FEops nv

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/feops

- Industry: Healthcare IT
- Headquarters: Gent, Belgium
- Website: www.feops.com
- Total disclosed funding: $8.7M
- Latest round: Series B (Sep 22, 2017)
- Investors on record: 3

## About

FEops nv is a technology firm that develops advanced AI-driven solutions designed to enhance the assessment and treatment of structural heart diseases.Founded in 2009 in Gent, Belgium, FEops nv specializes in innovative technologies for the healthcare sector. The company is led by Matthieu De Beule, who also serves as the CEO. FEops has engaged in 4 deals, with its most recent funding round occurring on October 28, 2022, when it raised EUR 3.3 million in VENTURE DEBT from the European Innovation Council and other investors. To date, FEops has raised a total of EUR 6.0 million.FEops offers the FEops HEARTguide™, a cloud-based platform that leverages predictive simulation technology and artificial intelligence to analyze cardiac CT scans. This product aims to improve procedural efficiency and patient outcomes in complex cardiac interventions, including transcatheter aortic valve implantation (TAVI) and left atrial appendage occlusion (LAAO). Its clients include hospitals and cardiovascular centers across Europe, the United Kingdom, Canada, Australia, and the United States, providing critical support to healthcare professionals in making informed clinical decisions.In 2022, FEops reported an EBITDA of EUR -1,230,862.40. The company generates revenue through subscription access to its FEops HEARTguide™ platform, offering AI-enhanced anatomical analysis and simulation services tailored to TAVI and LAAO procedures. This B2B revenue model focuses on partnerships with healthcare providers and device manufacturers, integrating its technology into clinical workflows to improve patient care.Following its recent funding round in October 2022, FEops plans to utilize the EUR 3.3 million raised to expand its technology and continue enhancing its artificial intelligence-driven solutions. The company is focused on entering new markets and geographic regions, although specific details on upcoming product launches or targeted regions have not been disclosed. The funding will support these initiatives, reinforcing FEops's commitment to advancing care in structural heart disease.

## Funding rounds

- Series B, Sep 22, 2017, $7.2M — Capricorn Partners, PMV, Valiance
- Series A, Jan 13, 2015, $1.5M — Capricorn Partners, PMV

## Investors

- Capricorn Partners (https://capitalatlas.ai/funds/capricorn-partners) — Series A, Series B
- PMV (https://capitalatlas.ai/funds/pmv) — Series A, Series B
- Valiance (https://capitalatlas.ai/funds/valiance) — Series B